PainChek Ltd · ASX:PCK
PainChek — Investor Presentation (August 2022)
31 slides from PainChek's investor presentation, August 2022

Slide 1: Company Presentation August 2022
Company Presentation August 2022 Philip Daffas - CEO & Managing Director PAINCHEK LTD | ASX:PCK 1

Slide 2: Corporate Overview
C O R P O R AT E O V E R V I E W • PainChek’s SAAS AI Platform uses smart devices to accurately evaluate patients’ pain level • PainChek improves Patient care – and saves time and money for provider • 126,000 contracted beds across 1,500 facilities globally - 60% market share in Australia, UK sales

Slide 3: Our purpose is to give a voice to people who cannot reliably verbalise their pain
Our purpose is to give a voice to people who cannot reliably verbalise their pain 3 |

Slide 4: The Breadth of the PainChek Global Market Opportunity
T H E B R E A D T H O F T H E PA I N C H E K G L O B A L M A R K E T O P P O R T U N I T Y 400M pre-verbal children 25-42% of hospital beds occupied by people with dementia 57M people living with dementi >150M expected by 2050 1. Ecology Communications Group. www.ecology.com/birth-death-rates 2. Wor

Slide 5: PainChek Adult – A Universal Fully Digital Solution
PA I N C H E K A D U LT – A U N I V E R S A L F U L LY D I G I TA L S O L U T I O N • Mobile point of care and real time pain assessment Ap • Fully digital technology – from sales, delivery and implementation – to assess pain or document pain for all people, everywhere • SaaS Business model – B2B an

Slide 6: PainChek Market Strategy and Pricing Strategy
PA I N C H E K M A R K E T S T R AT E G Y A N D P R I C I N G S T R AT E G Y BUSINESS MODEL TARGET MARKETS/USERS • $50/bed/annum in Aged Care B2B Enterprise: licence • Dementia &/geriatric ward • 20-25% cost of sales (including integration fees • Hospital • ER/Post surgical infant car • $1/day bed i

Slide 7: Adult Market Opportunity
A D U LT M A R K E T O P P O R T U N I T Y ENTERPRISE DEMENTIA MARKET VALUE Aus UK US ROW est TOTAL No. Aged Care Beds 0.22m 0.54m 1.7m 4.5m 6.96m Annual Market Value @ A$11m A$26m A$81m A$216 A$334m A$4 per bed per month PainChek Adult CONSUMER DEMENTIA MARKET VALUE Aus EU US ROW est TOTAL No. of P

Slide 8: The PainChek Pain Assessment Tool - Background
T H E PA I N C H E K PA I N A S S E S S M E N T T O O L - B A C K G R O U N D giving a voice to people who cannot reliably verbalise their pai 8 n

Slide 9: The Evolution of Pain Assessment
T H E E V O L U T I O N O F PA I N A S S E S S M E N T PainChek® builds on the benefits of the Abbey Pain Scale1, maintaining clinical practice while improving clinical process & brings it into the digital age by: Legacy Pain Assessment Tools Using video/AI to automate the facial expression assessme

Slide 10: Universal Pain Assessment Solution for All People Everywhere
U N I V E R S A L PA I N A S S E S S M E N T S O L U T I O N F O R A L L P E O P L E E V E R Y W H E R E Providing the right pain assessment solution for those whose ability to communicate fluctuates 10

Slide 11: Existing PainChek and Medication Management Process
E X I S T I N G PA I N C H E K A N D M E D I C AT I O N M A N A G E M E N T PROCESS IN AGED CARE AND HOME CARE Internationally, PainChek is currently engaged with 10+ medication management/eMAR and Pharmacy providers, covering ~350,000+ residential aged care places. Where complete, integrations with

Slide 12: Advanced pain management analytics
Advanced pain management analytics 12

Slide 13: PainChek in Residential Aged Care
PainChek in Residential Aged Care 1 8 - m o n t h c a s e s t u d y c o n d u c t e d b y O r c h a r d C a r e H o m e s , a n E n g l a n d b a s e d R A C P r o v i d e r, saw the following results after implementing PainChek. Metric Outcome 29% of residents had a Benzodiazepine prescribed dose r

Slide 14: Business Growth Reflected in Training & Clinical Use
BUSINESS GROWTH REFLECTED IN TRAINING & CLINICAL USE PAINCHEK® USERS TRAINED NUMBER OF PAINCHEK ASSESSMENTS DIGITALLY PER QUARTER 1,345,86 10000 Cumulative 278140 280,000 7500 219747 210,000 204992 172225 5000 140,000 126087 2500 70,000 0 Jun-25 Sept-25 Dec-25 Mar-26 Jun-26 eLearning Classrom (video

Slide 15: Growth in Global Commercial Subscriptions
GROWTH IN GLOBAL COMMERCIAL SUBSCRIPTIONS - DRIVEN BY SUCCESSFUL CONVERSION OF GOVERNMENT FUNDED BEDS CONTRACTED AND IMPLEMENTED CONTRACTED AND IMPLEMENTED NUMBER ANNUAL RECURRING REVENUE ($M) 160,000 $7.0 3.37 3.2044 70,293 3.0954 64,167 66,032 120,000 $5.3 2.6251 53,689 2.2681 46,843 80,000 $3.5 3

Slide 16: ANZ Sales and Partnership Milestones – FY22 YTD
A N Z S A L E S A N D PA R T N E R S H I P M I L E S T O N E S – F Y 2 2 Y T D Sumerset Group NZ Joondalup Health Campus Finley Regional Care The Nulsen Group contracted for full PainChek (Ramsay Health Care) contracted as PainChek’s contracted as PainChek’s rollou contracted as PainChek first comme

Slide 17: UK - Rapid Entry into the Residential Aged Care Market
U K - R A P I D E N T RY I N TO T H E 4 4 0 , 0 0 0 B E D R E S I D E N T I A L A G E D C A R E MARKET “The greatest achievement to date s a marked decrease in antipsychotic use in those living with dementia. UK market traction growing – Government funded pilots in New sales with Care UK and Cheryl

Slide 18: Integration Partners in Australia, UK, NZ and Canada
INTEGRATION PARTNERS in Australia, UK, NZ and Canada provide access to more than 470,000 aged care beds PainChek works with aged care management and medication Integration partners support the drive to better care delivery and management systems covering more than 180,000 aged care eliminating dupli

Slide 19: Home Care Partners
H O M E C A R E PA R T N E R S In late 2021, PainChek announced our partnership with Many of PainChek’s existing integration partners also provide MPS Connect, a subsidiary of Sigma Healthcare. service to the large and growing home care market, both in Australia and globally. The PainChek Universal

Slide 20: Infant App Regulatory Cleared for Sale in Multiple Markets
INFANT APP REGULATORY CLEARED FOR SALE IN MULTIPLE MARKETS* World first facial recognition UK, CE & TGA clearance for Infant version PCK infant clinical study technology to assess pre-verbal achieved Q2 CY21 published in Lancet Digital infant post-procedural pain through US market entry as a Clinica

Slide 21: Pre-Verbal Children's Pain Assessment Is a Large Global Market Opportunity
P R E - V E R B A L C H I L D R E N ’ S PA I N A S S E S S M E N T IS A LARGE GLOBAL MARKET OPPORTUNITY CONSUMER PRE-VERBAL CHILDREN MARKET VALUE Indicative App Price A$10/month A grant from the FDA is supporting Duke University organisations to work toward Net Revenue identifying high-quality clini

Slide 22: How PainChek Infant Can Support HCPs & Parents
H O W PA I N C H E K ® I N FA N T C A N S U P P O R T H C P ’ s & PA R E N T S B E T T E R M A N A G E P O S T P R O C E D U R A L PA I N F O R I N FA N T S 1. 2. 3. 4. Infant prior to PainChek Infant is available Parent can access PainChek Parent can utilise PainChek vaccination or post surgical fo

Slide 23: PainChek Children
PainChek Infant PainChek for Children with Disabilities PainChek® Children 1 month to 3 years PainChek for Children with Dementia (4) 5 years to 12 years 12 years to 18 years 23

Slide 24: PainChek's Global Market Access & Expansion Focus
PA I N C H E K ’ S G L O B A L M A R K E T A C C E S S & E X PA N S I O N F O C U S Canada Europe (EU • Partnership with • Targeting RAC beds and Home care AlayaCare dementia patients in EU • Exploring additional Aged • Exploring International partnerships Care and Home Care U with large corporate p

Slide 25: US Market Focus
US MARKET FOCUS FDA adult clearance anticipated in 2023 CDS infant clearance – submitted H2CY22 - Intended to support US COVID-19 infant vaccination roll-ou FDA clearance would give PainChek access to >70% of the global device market 25 t

Slide 26: PainChek Key Pillars FY23
PAINCHEK KEY PILLARS FY23 PainChek announced a $4.59m capital raising during June 2022, allowing the business to continue to focus on its key pillars CORE RAC FOCUS ON STRATEGIC NEW MARKET COMMERCIALISATION PRODUCT & GLOBAL EXPANSIO OF INFANT AP MARKET ENTRIE • Implement contracted beds across • Ini

Slide 27: The Team
THE TEAM Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam CEO & Managing Chief Scientific Officer Head of Operations CFO Director, MBA, BSc PhD, MPS Philip is a highly accomplished global Jeff is a professor in the School of Pharmacy, Andy is a Psychologist, management Iain has over 20 year

Slide 28: The Board
THE BOARD John Murray Chairman John Murra Philip Daffas Ross Harrick Adam Davey Cynthia Payn Non-Exec Chair CEO & Managing Non-Exec Director Non-Exec Director Non-Exec Director Director 25 years in tech & Venture Philip is a highly Senior global medical Corporate finance executive 30 years executive

Slide 29: Corporate Summary
CORPORATE SUMMARY Financial information Share price (12 August 2022) A$0.029 Shares on issue 1,296.4m Market capitalisation A$37.6m Cash (3 August 2022)* A$8.3m Unlisted options/performance rights 40.6m Debt Nil Top shareholders % Peters Investments Proprietary Ltd 9.14% Board & key staff 4.2% *Afte

Slide 30: Investment Highlights
INVESTMENT HIGHLIGHTS DOMINANT MARKET POSITIO STRONG REVENUE GROWTH 60% market share in Australia , accelerating presence in the Q4 FY22 Customer revenue up 10% on prior quarter to UK and New Zealand, 126,000 contracted beds across 1,500 $333k. Customer receipts $585k in the quarter. facilities glob

Slide 31: Contact
C O N TA C T Philip D affa s, CEO & MD philip.daffas@painchek.com 31
Source: Internet Archive copy of painchek.com
More decks from PainChek Ltd
Shareholder Meeting (November 2026)14 slides · Nov 4, 2026
Shareholder Meeting (November 2025)28 slides · Nov 26, 2025
Investor Presentation (October 2025)27 slides · Oct 31, 2025
Investor Presentation (July 2025)34 slides · Jul 28, 2025
Earnings Presentation (May 2025)32 slides · May 1, 2025
Q1 FY25 Earnings Presentation32 slides · Oct 30, 2024